Market Cap 402.99M
Revenue (ttm) 266.27M
Net Income (ttm) -50.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -18.94%
Debt to Equity Ratio -7.80
Volume 1,273,100
Avg Vol 1,496,774
Day's Range N/A - N/A
Shares Out 64.69M
Stochastic %K 35%
Beta 1.04
Analysts Strong Sell
Price Target $19.40

Company Profile

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 949 284 4555
Address:
520 Newport Center Drive, Suite 1200, Newport Beach, United States
PremarketAnalysis
PremarketAnalysis Oct. 10 at 11:40 PM
$EOLS SignalEngine: Bullish 80/20, Algo Vol 78%, Org Vol 22%, BRX 20%. Algo Intent: constructive recovery forming.. momentum rebuilding through steady bid support. Momentum Feed: https://premarketanalysis.com/#momentum=EOLS
0 · Reply
Mandi63
Mandi63 Oct. 10 at 1:55 PM
$AEON ABP 450 is already being sold though their European partner $EOLS worldwide..FDA approval in USA coming..new CEO YEARS OF experienced in BIOTECH
0 · Reply
Estimize
Estimize Oct. 9 at 11:06 AM
Wall St is expecting -0.15 EPS for $EOLS Q3 [Reporting 11/11 AMC] http://www.estimize.com/intro/eols?chart=historical&metric_name=eps&utm_c
0 · Reply
Longboardsoul
Longboardsoul Oct. 1 at 5:17 PM
$EOLS This stock is aids
0 · Reply
Damian23
Damian23 Sep. 25 at 3:49 PM
$EOLS I did again my calculation , I think they could need more money so I assumed 15% dilution, the consumer sentiment with the tariffs is not good right now: Peak sales target 2027: $495 million. Conservative 2x peak sales EV: 2×495=990 2×495=990 million USD. Shares outstanding Sept 2025: 64.7 million. Assuming 15% dilution → 74.5 million diluted shares. Cash on hand Q2 2025: $61.7 million. Debt outstanding: $155 million. Cash raised from dilution (9.7 million shares × $6): $58.2 million. Total cash = $61.7M + $58.2M = $119.9 million. Adjusted EV considering debt: $990M + $155M (debt) - $119.9M (cash) = $1,025.1 million. Equity value = EV - debt + cash = $1,025.1 million - $155 million + $119.9 million = $990 million Fair value per share = $990 million / 74.5 million = approx $13.29 per share. Current share price approx $6, 8I assumed they dillut at currentl evels) EV/Sales ratio with $300 million 2025 revenue = 995m/300m=3.3× 995m/300m=3.3×, aligned with aesthetics growth peers.
1 · Reply
lknite
lknite Sep. 23 at 4:41 PM
$EOLS /me gives eols a warm loving smile
0 · Reply
dabbber
dabbber Sep. 17 at 2:50 PM
$EOLS fulled ported at 6.60
0 · Reply
lknite
lknite Sep. 16 at 11:18 PM
$EOLS /me nudges eols, wake up
1 · Reply
lknite
lknite Sep. 15 at 6:07 PM
$EOLS amazing
1 · Reply
lknite
lknite Sep. 15 at 2:44 PM
$EOLS looks like the market makers are pushing it down for a better entry before letting it fly
0 · Reply
Latest News on EOLS
Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:15 PM EDT - 2 months ago

Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript


Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings

Jul 21, 2025, 5:20 PM EDT - 2 months ago

Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings


Evolysse™ Recognized in 2025 Shape Skin Awards

Jun 10, 2025, 8:00 AM EDT - 4 months ago

Evolysse™ Recognized in 2025 Shape Skin Awards


Evolus Announces Departure of its Chief Financial Officer

May 27, 2025, 4:15 PM EDT - 4 months ago

Evolus Announces Departure of its Chief Financial Officer


Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:13 PM EDT - 5 months ago

Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript


Evolus Reports First Quarter 2025 Results

May 7, 2025, 4:05 PM EDT - 5 months ago

Evolus Reports First Quarter 2025 Results


Evolus to Report First Quarter Financial Results on May 7, 2025

Apr 23, 2025, 8:00 AM EDT - 6 months ago

Evolus to Report First Quarter Financial Results on May 7, 2025


Evolus Announces Commercial Launch of Evolysse™

Apr 16, 2025, 8:00 AM EDT - 6 months ago

Evolus Announces Commercial Launch of Evolysse™


Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 11:18 PM EST - 7 months ago

Evolus, Inc. (EOLS) Q4 2024 Earnings Call Transcript


US FDA approves Evolus' anti-wrinkle gels

Feb 13, 2025, 1:45 PM EST - 8 months ago

US FDA approves Evolus' anti-wrinkle gels


Evolus Reports Third Quarter 2024 Results

Nov 6, 2024, 4:05 PM EST - 1 year ago

Evolus Reports Third Quarter 2024 Results


Evolus to Participate in Stifel 2024 Healthcare Conference

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Evolus to Participate in Stifel 2024 Healthcare Conference


Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 10:22 PM EDT - 1 year ago

Evolus, Inc. (EOLS) Q2 2024 Earnings Call Transcript


Evolus to Hold Investor Day on September 12, 2024

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Evolus to Hold Investor Day on September 12, 2024


Evolus: Chiseling Away At The Aesthetic Market

May 22, 2024, 7:00 AM EDT - 1 year ago

Evolus: Chiseling Away At The Aesthetic Market


PremarketAnalysis
PremarketAnalysis Oct. 10 at 11:40 PM
$EOLS SignalEngine: Bullish 80/20, Algo Vol 78%, Org Vol 22%, BRX 20%. Algo Intent: constructive recovery forming.. momentum rebuilding through steady bid support. Momentum Feed: https://premarketanalysis.com/#momentum=EOLS
0 · Reply
Mandi63
Mandi63 Oct. 10 at 1:55 PM
$AEON ABP 450 is already being sold though their European partner $EOLS worldwide..FDA approval in USA coming..new CEO YEARS OF experienced in BIOTECH
0 · Reply
Estimize
Estimize Oct. 9 at 11:06 AM
Wall St is expecting -0.15 EPS for $EOLS Q3 [Reporting 11/11 AMC] http://www.estimize.com/intro/eols?chart=historical&metric_name=eps&utm_c
0 · Reply
Longboardsoul
Longboardsoul Oct. 1 at 5:17 PM
$EOLS This stock is aids
0 · Reply
Damian23
Damian23 Sep. 25 at 3:49 PM
$EOLS I did again my calculation , I think they could need more money so I assumed 15% dilution, the consumer sentiment with the tariffs is not good right now: Peak sales target 2027: $495 million. Conservative 2x peak sales EV: 2×495=990 2×495=990 million USD. Shares outstanding Sept 2025: 64.7 million. Assuming 15% dilution → 74.5 million diluted shares. Cash on hand Q2 2025: $61.7 million. Debt outstanding: $155 million. Cash raised from dilution (9.7 million shares × $6): $58.2 million. Total cash = $61.7M + $58.2M = $119.9 million. Adjusted EV considering debt: $990M + $155M (debt) - $119.9M (cash) = $1,025.1 million. Equity value = EV - debt + cash = $1,025.1 million - $155 million + $119.9 million = $990 million Fair value per share = $990 million / 74.5 million = approx $13.29 per share. Current share price approx $6, 8I assumed they dillut at currentl evels) EV/Sales ratio with $300 million 2025 revenue = 995m/300m=3.3× 995m/300m=3.3×, aligned with aesthetics growth peers.
1 · Reply
lknite
lknite Sep. 23 at 4:41 PM
$EOLS /me gives eols a warm loving smile
0 · Reply
dabbber
dabbber Sep. 17 at 2:50 PM
$EOLS fulled ported at 6.60
0 · Reply
lknite
lknite Sep. 16 at 11:18 PM
$EOLS /me nudges eols, wake up
1 · Reply
lknite
lknite Sep. 15 at 6:07 PM
$EOLS amazing
1 · Reply
lknite
lknite Sep. 15 at 2:44 PM
$EOLS looks like the market makers are pushing it down for a better entry before letting it fly
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 11 at 11:26 AM
$EOLS Really good write-up that perfectly summarizes EOLS's present situation. So if you want to bring your EOLS knowledge up to date or just discover EOLS, this is required reading. https://beyondspx.com/quote/EOLS/analysis/evolus-cold-x-innovation-and-portfolio-powering-growth-amidst-aesthetic-headwinds-nasdaq-eols
0 · Reply
BioTuesdays
BioTuesdays Sep. 8 at 3:56 PM
$EOLS has announced the appointment of Tatjana Mitchell as chief financial officer (CFO), effective today. https://biotuesdays.com/2025/09/08/tatjana-mitchell-joins-evolus-as-cfo/
1 · Reply
lknite
lknite Sep. 2 at 4:36 PM
0 · Reply
lknite
lknite Aug. 29 at 10:26 PM
$EOLS I once heard, "trading stocks is supposed to feel easy". Buying EOLS as this price is exactly that. I know its not super dramatic, just doubling your moneybover a few weeks.
0 · Reply
lknite
lknite Aug. 29 at 10:23 PM
$EOLS up up up i need to get my daytradingbuyingpower back up
0 · Reply
lknite
lknite Aug. 28 at 11:42 PM
$EOLS let's go!!!
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 25 at 12:31 PM
$EOLS (+3.5% pre) Evolus reports positive trial results for Evolysse Sculpt dermal filler https://ooc.bz/l/75038
0 · Reply
TA_Kongen
TA_Kongen Aug. 25 at 12:09 PM
$EOLS Ahh this is botox lmfao wtf
1 · Reply
TA_Kongen
TA_Kongen Aug. 25 at 12:05 PM
$EOLS ??? Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp Looks good, no reaction.
0 · Reply
USA_toinfinityandbeyond
USA_toinfinityandbeyond Aug. 21 at 9:40 AM
$EOLS "Mizuho Reiterates Outperform Rating on Evolus" https://www.investing.com/news/pro/mizuho-maintains-evolus-at-outperform-with-a-price-target-of-1900-4203836
0 · Reply
Damian23
Damian23 Aug. 20 at 4:56 PM
$EOLS Q2 2025 revenue: $69.4 million; 2025 guidance: $295$305 million. Current market cap: $461 million (updated). Debt: $154.5 million; Cash: $61.7 million. Shares outstanding: 64 million. Enterprise Value (EV) = Market Cap + Debt - Cash = 461M + 154.5M - 61.7M = $553.8 million. EV / 2025 revenue midpoint ($300M) = 553.8M / 300M = ~1.85x. Assume conservative 20% annual revenue growth after 2025. Projected revenue 2026 = $295M × 1.2 = $354 million. Projected revenue 2027 = $354M × 1.2 = $425 million. Using EV/Revenue multiple of 1.85x for 2027 (conservative): EV 2027 = $425M × 1.85 = $786 million. Equity value 2027 = EV - Debt + Cash = 786M - 154.5M + 61.7M = $693 million. Fair value per share = $693M / 64M = $10.8 per share. Current price ~$7.20 (based on market cap and shares) vs. fair value $10.8. Upside potential under conservative assumptions is about 50%.
0 · Reply
prismmarketview
prismmarketview Aug. 20 at 2:18 PM
(NASDAQ: $EOLS) @Evolus has submitted its PMA application to the FDA for Evolysse™ Sculpt, its flagship injectable HA gel targeting mid-face volume restoration. Backed by strong pivotal trial data, Sculpt leverages innovative Cold-X™ technology and is expected to enter the highest-value dermal filler segment, with FDA approval anticipated in 2H 2026. This milestone expands Evolus’ portfolio and positions the company for continued growth in aesthetics. https://prismmarketview.com/evolus-submits-fda-premarket-approval-application-for-evolysse-sculpt-injectable-ha-gel/
0 · Reply